Involving Patients in Their Care Decisions and JAMA Editorial: The New Cholesterol and Blood Pressure Guidelines: Perspective on the Path Forward

Status

Involving Patients in Their Care Decisions and JAMA Editorial: The New Cholesterol and Blood Pressure Guidelines: Perspective on the Path Forward

Krumholz HM. The New Cholesterol and Blood Pressure Guidelines: Perspective on the Path Forward. JAMA. 2014 Mar 29. doi: 10.1001/jama.2014.2634. [Epub ahead of print] PubMed PMID: 24682222.

http://jama.jamanetwork.com/article.aspx?articleid=1853201

Here is an excellent editorial that highlights the importance of patient decision-making.  We thank the wonderful Dr. Richard Lehman, MA, BM, BCh, Oxford, & Blogger, BMJ Journal Watch, for bringing this to our attention. [Note: Richard’s wonderful weekly review of medical journals—informative, inspiring and oh so droll—is here.]

We have often observed that evidence can be a neutralizing force. This editorial highlights for us that this means involving the patient in a meaningful way and finding ways to support decisions based on patients’ personal requirements. These personal “patient requirements” include health care needs and wants and a recognition of individual circumstances, values and preferences.

To achieve this, we believe that patients should receive the same information as clinicians including what alternatives are available, a quantified assessment of potential benefits and harms of each including the strength of evidence for each and potential consequences of making various choices including things like vitality and cost.

Decisions may differ between patients, and physicians may make incorrect assumption about what most matters to patients of which there are many examples in the literature such as in the citations below.

O’Connor A. Using patient decision aids to promote evidence-based decision making. ACP J Club. 2001 Jul-Aug;135(1):A11-2. PubMed PMID: 11471526.

O’Connor AM, Wennberg JE, Legare F, Llewellyn-Thomas HA,Moulton BW, Sepucha KR, et al. Toward the ‘tipping point’: decision aids and informed patient choice. Health Affairs 2007;26(3):716-25.

Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005 Jan 1-7;365(9453):82-93. PubMed PMID: 15639683.

Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Légaré F, Thomson R. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD001431. Review. PubMed PMID: 21975733.

Wennberg JE, O’Connor AM, Collins ED, Weinstein JN. Extending the P4P agenda, part 1: how Medicare can improve patient decision making and reduce unnecessary care. Health Aff (Millwood). 2007 Nov-Dec;26(6):1564-74. PubMed PMID: 17978377.

Facebook Twitter Linkedin Digg Delicious Reddit Stumbleupon Tumblr Email

Can Clinical Guidelines be Trusted?

Status

Can Clinical Guidelines be Trusted?

In a recent BMJ article, “Why we can’t trust clinical guidelines,” Jeanne Lenzer raises a number of concerns regarding clinical guidelines[1]. She begins by summarizing the conflict between 1990 guidelines recommending steroids for acute spinal injury versus 2013 cllinical recommendations against using steroids in acute spinal injury. She then asks, “Why do processes intended to prevent or reduce bias fail?

Her proposed answers to this question include the following—

  • Many doctors follow guidelines, even if not convinced about the recommendations, because they fear professional censure and possible harm to their careers.
    • Supporting this, she cites a poll of over 1000 neurosurgeons which showed that—
      • Only 11% believed the treatment was safe and effective.
      • Only 6% thought it should be a standard of care.
      • Yet when asked if they would continue prescribing the treatment, 60% said that they would. Many cited a fear of malpractice if they failed to follow “a standard of care.” (Note: the standard of care changed in March 2013 when the Congress of Neurological Surgeons stated there was no high quality evidence to support the recommendation.)
  • Clinical guideline chairs and participants frequently have financial conflicts.
    • The Cochrane reviewer for the 1990 guideline she references had strong ties to industry.

Delfini Comment

  • Fear-based Decision-making by Physicians

We believe this is a reality. In our work with administrative law judges, we have been told that if you “run with the pack,” you better be right, and if you “run outside the pack,” you really better be right. And what happens in court is not necessarily true or just. The solution is better recommendations constructed from individualized, thoughtful decisions based on valid critically appraised evidence found to be clinically useful, patient preferences and other factors. The important starting place is effective critical appraisal of the evidence.

  • Financial Conflicts of Interest & Industry Influence

It is certainly true that money can sway decisions, be it coming from industry support or potential for income. However, we think that most doctors want to do their best for patients and try to make decisions or provide recommendations with the patient’s best interest in mind. Therefore, we think this latter issue may be more complex and strongly affected in both instances by the large number of physicians and others involved in health care decision-making who 1) do not understand that many research studies are not valid or reported sufficiently to tell; and, 2) lack the skills to be able to differentiate reliable studies from those which may not be reliable.

When it comes to industry support, one of the variables traveling with money includes greater exposure to information through data or contacts with experts supporting that manufacturer’s products. We suspect that industry influence may be less due to financial incentives than this exposure coupled with lack of critical appraisal understanding. As such, we wrote a Letter to the Editor describing our theory that the major problem of low quality guidelines might stem from physicians’ and others’ lack of competency in evaluating the quality of the evidence. Our response is reproduced here.

Delfini BMJ Rapid Response [2]:

We (Delfini) believe that we have some unique insight into how ties to industry may result in advocacy for a particular intervention due to our extensive experience training health care professionals and students in critical appraisal of the medical literature. We think it is very possible that the outcomes Lenzer describes are less due to financial influence than are due to lack of knowledge. The vast majority of physicians and other health care professionals do not have even rudimentary skills in identifying science that is at high to medium risk of bias or understand when results may have a high likelihood of being due to chance. Having ties to industry would likely result in greater exposure to science supporting a particular intervention.

Without the ability to evaluate the quality of the science, we think it is likely that individuals would be swayed and/or convinced by that science. The remedy for this and for other problems with the quality of clinical guidelines is ensuring that all guideline development members have basic critical appraisal skills and there is enough transparency in guidelines so that appraisal of a guideline and the studies utilized can easily be accomplished.

References

1. Lenzer J. Why we can’t trust clinical guidelines. BMJ 2013; 346:f3830

2. Strite SA, Stuart M. BMJ Rapid Response: Why we can’t trust clinical guidelines. BMJ 2013;346:f3830; http://www.bmj.com/content/346/bmj.f3830/rr/651876

Facebook Twitter Linkedin Digg Delicious Reddit Stumbleupon Tumblr Email

Review of Endocrinology Guidelines

Status

Review of Endocrinology Guidelines

Decision-makers frequently rely on the body of pertinent research in making decisions regarding clinical management decisions. The goal is to critically appraise and synthesize the evidence before making recommendations, developing protocols and making other decisions. Serious attention is paid to the validity of the primary studies to determine reliability before accepting them into the review.  Brito and colleagues have described the rigor of systematic reviews (SRs) cited from 2006 until January 2012 in support of the clinical practice guidelines put forth by the Endocrine Society using the Assessment of Multiple Systematic Reviews (AMSTAR) tool [1].

The authors included 69 of 2817 studies. These 69 SRs had a mean AMSTAR score of 6.4 (standard deviation, 2.5) of a maximum score of 11, with scores improving over time. Thirty five percent of the included SRs were of low-quality (methodological AMSTAR score 1 or 2 of 5, and were cited in 24 different recommendations). These low quality SRs were the main evidentiary support for five recommendations, of which only one acknowledged the quality of SRs.

The authors conclude that few recommendations in field of endocrinology are supported by reliable SRs and that the quality of the endocrinology SRs is suboptimal and is currently not being addressed by guideline developers. SRs should reliably represent the body of relevant evidence.  The authors urge authors and journal editors to pay attention to bias and adequate reporting.

Delfini note: Once again we see a review of guideline work which suggests using caution in accepting clinical recommendations without critical appraisal of the evidence and knowing the strength of the evidence supporting clinical recommendations.

1. Brito JP, Tsapas A, Griebeler ML, Wang Z, Prutsky GJ, Domecq JP, Murad MH, Montori VM. Systematic reviews supporting practice guideline recommendations lack protection against bias. J Clin Epidemiol. 2013 Jun;66(6):633-8. doi: 10.1016/j.jclinepi.2013.01.008. Epub 2013 Mar 16. PubMed PMID: 23510557.

Facebook Twitter Linkedin Digg Delicious Reddit Stumbleupon Tumblr Email

Delfini Treatment Messaging Scripts™ Update

Status

 Messaging Scripts ™ Update

Delfini Messaging Scripts  are scripts for scripts. Years ago we were asked by a consultancy pharmacy to come up with a method to create concise evidence-based statements for various therapies.  That’s how we came up with our ideas for Messaging Scripts, which are targeted treatment messaging & decision support tools for specific clinical topics. Since working with that group, we created a template and some sample scripts which have been favorably received wherever we have shown them.  The template is available at the link below, along with several samples.  Samples recently updated: Ace Inhibitors, Alendronate, Sciatica (Low Back Pain), Statins (two scripts) and Venous Thromboembolism (VTE) Prevention in Total Hip and Total Knee Replacement.

 http://www.delfini.org/page_SamePage_RxMessagingScripts.htm

Facebook Twitter Linkedin Digg Delicious Reddit Stumbleupon Tumblr Email

Proton Beam Therapy For Prostate Cancer

Status

Proton Beam Therapy For Prostate Cancer

As of this writing, there is insufficient evidence to conclude that proton beam is more effective in treating prostate cancer than conventional radiation therapy; and there is no evidence of significant differences between proton therapy and radiation therapy in total serious adverse events.  Readers may be interested in a recent article where the investigators point out that patients diagnosed with prostate cancer and  living in areas where proton beam therapy is readily available are more likely to be treated with this new technology than with conventional radiation therapy. The cost of treating prostate cancer with proton beam therapy can exceed $50,000 per patient which is twice the cost of radiation therapy. Increasingly, we are seeing new technologies with staggering costs. In prostate cancer, for example, as we write this, proton centers are being built all over the country at a cost of up to $200 million.

Reference

Aaronson DS, Odisho AY, Hills N, Cress R, Carroll PR, Dudley RA, Cooperberg MR. Proton beam therapy and treatment for localized prostate cancer: if you build it, they will come. Arch Intern Med. 2012 Feb 13;172(3):280-3. PubMed PMID:22332166.

Facebook Twitter Linkedin Digg Delicious Reddit Stumbleupon Tumblr Email

Critical Appraisal Matters

Status

Critical Appraisal Matters

Mike and I make it a practice to study the evidence on the evidence.  Doing effective critical appraisal to evaluate the validity and clinical usefulness of studies makes a difference.  This page on our website may be our most important one and we have now added a 1-page fact sheet for downloading: http://www.delfini.org/delfiniFactsCriticalAppraisal.htm

Facebook Twitter Linkedin Digg Delicious Reddit Stumbleupon Tumblr Email

A Performance Measure for Overuse? The Loosening Of Tight Control In Diabetes

Status

A Performance Measure for Overuse?  The Loosening Of Tight Control In Diabetes

Performance measures for tighter glycemic control appeared following the DCCT trial (Type 1 diabetes) in 1993 and the UKPDS trial (type 2 diabetes) in 1998.[1],[2] About 7 years ago groups recommended that glycohemoglobin concentrations be less than 7%, even though clear evidence of improved net outcomes was lacking.[3]

Now in an editorial in the online version of Archives of Internal Medicine, Pogach and Aron have nicely summarized details of this journey into overuse of hypoglycemic agents resulting in the problem of harms probably outweighing benefits—at least for some diabetics—in an editorial entitled, The Other Side of Quality Improvement in Diabetes for Seniors: A Proposal for an Overtreatment Glycemic Measure.[4]

The authors review the ACCORD, ADVANCE and VADT trials and remind readers that tight glycemic control did not yield cardiovascular benefits in these trials and that severe hypoglycemia occurred in the intensive treatment groups of all three trials. Of concern was the finding that ACCORD was terminated early because of increased mortality in the intensive glycemic treatment group. These trials appear to have increased concern about the risks of severe hypoglycemia in elderly patients and patients with existing cardiovascular disease, and the National Committee for Quality Assurance Healthcare Effectiveness Data and Information Set (HEDIS) modified its glycohemoglobin goal to less than 7% for persons younger than 65 years without cardiovascular disease or end-stage complications and diabetes and established a new, more relaxed goal of less than 8% for persons 65 to 74 years of age.

Kirsh and Aron took this a step further in 2011 and proposed a glycohemoglobin concentration of less than 7.0% as a threshold measure of potential overtreatment of hyperglycemia in  persons older than 65 years who are at high risk for hypoglycemia. They point out that the risk for hypoglycemia could be assessed by utilizing data from the electronic medical record regarding prescriptions for insulin and/or sulfonylurea medications and retrieving information on comorbidities such as chronic kidney disease, cognitive impairment or dementia, neurologic conditions that may interfere with a successful response to a hypoglycemic event.[5]

This commentary is worth reading and thinking about. We agree with them that the time has come to take more actions to prevent the risk of possible overtreatment in diabetes.



[1] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993 Sep 30;329(14):977-86. PubMed PMID: 8366922.

[2]  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998 Nov 7;352(9139):1558. PubMed PMID: 9742977.

 [3]  Pogach L, Aron DC. Sudden acceleration of diabetes quality measures. JAMA. 2011 Feb 16;305(7):709-10. PubMed PMID: 21325188.

[4] Published Online: September 10, 2012. doi:10.1001/archinternmed.2012.4392.

[5]  Kirsh SR, Aron DC. Choosing targets for glycaemia, blood pressure and low-density lipoprotein cholesterol in elderly individuals with diabetes mellitus. Drugs Aging. 2011 Dec 1;28(12):945-60. doi: 10.2165/11594750-000000000-00000. PubMed PMID: 22117094.

 

Facebook Twitter Linkedin Digg Delicious Reddit Stumbleupon Tumblr Email

Best Care at Lower Cost: The Path to Continuously Learning Health Care in America

Status

Best Care at Lower Cost: The Path to Continuously Learning Health Care in America

“If home building were like health care, carpenters, electricians, and plumbers each would work with different blueprints, with very little coordination.”

“If airline travel were like health care, each pilot would be free to design his or her own preflight safety check, or not to perform one at all.”

The Institute of Medicine (IOM) has just released this latest “state of our health care” report which is well worth reading. [1]  We have a long ways to go before we have a health system. The report, released September 6, 2012, concludes that our dysfunctional health care system wastes about $760 billion each year. Much of the waste is due to inefficiencies and administrative duplications, but $210 billion of the waste is due to unnecessary services (e.g., overuse, unnecessary choice of higher cost services) and $55 billion is wasted on missed primary, secondary and tertiary prevention opportunities.

Here are just a few of the interesting points and recommendations the 18 authors make:

  • The volume of the biomedical and clinical knowledge base has rapidly expanded, with research publications having risen from more than 200,000 a year in 1970 to more than 750,000 in 2010;
  • We can achieve striking improvements in safety, quality, reliability, and value through the use of systematic evidence-based process improvement methods;
  • We need digital platforms supporting real-time access to knowledge;
  • We need to  engage empowered patients;
  • We need full transparency in all we do;
  • We need improved decision support; improved patient-centered care through tools that deliver reliable, current clinical knowledge to the point of care; and, organizations’ support for, and adoption of, incentives that encourage the use of these tools.

The pre-publication issue of this IOM report is currently available free of charge at this URL.[2]



[1] Smith M, Cassell G, Ferguson B, Jones C, Redberg R; Institute of Medicine of the National Academies. Best care at lower cost: the path to continuously learning health care in America. http://iom.edu/Activities/Quality/LearningHealthCare/2012- SEP-06.aspx.

Facebook Twitter Linkedin Digg Delicious Reddit Stumbleupon Tumblr Email

Divulging Information to Patients With Poor Prognoses

Status

Divulging Information to Patients With Poor Prognoses

We have seen several instances where our colleagues’ families have been given very little prognostic information by their physicians in situations where important decisions involving benefits versus harms, quality of life and other end of life decisions must be made. In both cases when a clinician in the family presented the evidence and prognostic information, decisions were altered.

We were happy to see a review of this topic by Mack and Smith in a recent issue of the BMJ.[1] In a nutshell the authors point out that—

  • Evidence consistently shows that healthcare professionals are hesitant to divulge prognostic information due to several underlying misconceptions. Examples of misconceptions—
    • Prognostic information will make patients depressed
    • It will take away hope
    • We can’t be sure of the patient’s prognosis anyway
    • Discussions about prognosis are uncomfortable
  • Many patients are denied discussion about code status, advance medical directives, or even hospice until there are no more treatments to give  and little time left for the patient
  • Many patients lose important  time with their families and and spend more time in the hospital and in intensive care units than would be if prognostic information had been provided and different decisions had been made.

Patients and families want prognostic information which is required to make decisions that are right for them. This together with the lack of evidence that discussing prognosis causes depression, shortens life, or takes away hope and the huge problem of unnecessary interventions at the end of life creates a strong argument for honest communication about poor prognoses.

Reference

1. Mack JW, Smith TJ. Reasons why physicians do not have discussions about poor prognosis, why it matters, and what can be improved. J Clin Oncol. 2012 Aug 1;30(22):2715-7. Epub 2012 Jul 2. PubMed PMID: 22753911.

 

Facebook Twitter Linkedin Digg Delicious Reddit Stumbleupon Tumblr Email